In vitro activities of quinolones

Bibliography

• LESHER GY, TROELICH CJ, BRUNDAGE RP et a/.:1,8-M,naphthyridine derivatives, a new class of chemother-apy agents. J. Med. Chem. (1962) 5:1063–1065.
   Google Scholar
• KOGA H, ITOH A, MURAYAMA S, SUZUE S, IRIKURA T:Structure activity relationship, of antibacterial 6,7-and 7,8 disubstituted 1-alkyl-1,4-dihydro-4-oxaquinolone-3-carboxylic acids. J. Med. Chem. (1980) 23:1358–1362.
   PubMed Web of Science ®Google Scholar
• ALBRECHT R: Development of antibacterial agents ofthe nalidixic type. Prof Drug. Res. (1977) 21:9–104.
   PubMedGoogle Scholar
• MITCHER LA, DEVASTHALE P, ZAROD R: Structure activ-ity relationships. In: Hooper DC Wolfson, JS (Eds.) Qui-nolone antimicrobial agents, 2nd edn. American Society of Microbiology, Washington, (1993):3–51.
   Google Scholar
• DOMAGALA JM: Structure-activity and structure side-effect relationship for the quinolone antibacterials. J. Antimicrob. Chemother. (1994) 33:685–706.
   PubMed Web of Science ®Google Scholar
• BAUERNFEIND A: Comparison of the antibacterial ac-tivities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. (1997) 40:639–651.
   PubMed Web of Science ®Google Scholar
• WOODCOCK JM, ANDREWS JM, BOSWELL FJ, BRENWALDNP, WISE R: In vitro activity of Bay 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. (1997) 41:101–106.
   PubMed Web of Science ®Google Scholar
• CHILD J, ANDREWS J, BOSWELL F, BRENWALD N, WISE R:The in vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroqui-nolone agents. J. Antimicrob. Chemother. (1995) 35:869–876.
   PubMed Web of Science ®Google Scholar
• BRUEGGEMANN AB, KUGLER KC, DOERN GV: In vitro activity of Bay 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemo-ther. (1997) 41:1594–1597.
   PubMed Web of Science ®Google Scholar
• KLUGMANN KP, CAPPER T: Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. J. Antimicrob. Che-mother. (1997) 40:797–802.
   PubMed Web of Science ®Google Scholar
• BUXBAUM A et al: Comparative susceptibility of 1385 Streptococcus pneumoniae isolates to penicillin and quinolones. J. Antimicrb. Chemother. (1999) (In Press).
   Google Scholar
• ALDRIDGE KE, ASHCRAFT D, BOWMAN KA: Compara-tive in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant an-aerobes. Antimicrob. Agents Chemother. (1997) 41:484–487.
   PubMed Web of Science ®Google Scholar
• ALDRIDGE, KE, ASHCRAFT D: Comparison of the in vi-tro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important an-aerobes. Antimicrob. Agents Chemother. (1997) 41:709–711.
   PubMed Web of Science ®Google Scholar
• EDELSTEIN PH, EDELSTEIN MAC: WIN 57273 is bacteri-cidal for Legionella pneumophila grown in alveolar macrophages. Antimicrob. Agents Chemother. (1989) 33:2132–2136.
   PubMed Web of Science ®Google Scholar
• KOJIMA T, INOUE M, MITSUHASHI S: In vitro activity ofAT-4140 against clinical bacterial isolates. Antimicrob. Agents Chemother. (1989) 33:1980–1988.
   PubMed Web of Science ®Google Scholar
• ROLSTON KVI, NGUYEN H, MESSER M, LEBLANC B, HODH: GP BODEY: In vitro activity of sparfloxacin (CI-978, AT-4140) against clinical isolates from cancer pa-tients. Antimicrob. Agents Chemother. (1990) 34:2263–2266.
   PubMed Web of Science ®Google Scholar
• AKANIRO JC, VIDAURRE CE, STUTMAN HR, MARKS MI:Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from pa-tients with cystic fibrosis. Antimicrob. Agents Chemother. (1990) 34:1880–1884.
   PubMed Web of Science ®Google Scholar
• ARGUEDAS AG, AKANIRO JC, STUTMAN HR, MARKS MI: In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fi-brosis sputum. Antimicrob. Agents Chemother. (1990) 34:2223–2227.
   PubMed Web of Science ®Google Scholar
• ASAHARA M, TSUJI A, GOTO S, MASUDA K, KIUCHI A: In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative. Antimicrob. Agents Chemother. (1989) 33:1144–1152.
   PubMed Web of Science ®Google Scholar
• BARRY AL, FUCHS PC: Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. Eur. I Gun. Microbiol. In-fect. Dis. (1991) 10:168–171.
   PubMed Web of Science ®Google Scholar
• BAUERNFEIND A, PETERMIILLER C: In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur. J. Microbiol. (1983) 2:111–115.
   PubMedGoogle Scholar
• CHAUDHRY AZ, KNAPP CC, SIERRA-MADERO J, WASH-INGTON JA: Antistaphylococcal activities of sparfloxa-cin (CI-978; AT-4140), ofloxacin and ciprofloxacin. Antimicrob. Agents Chemother. (1990) 34:1843–1845.
   PubMed Web of Science ®Google Scholar
• BRYAN JP, WATERS C, SHEFFIELD J et al.: In vitro activi-ties of tosufloxacin, temafloxacin and A-56620 against pathogens of diarrhea. Antimicrob. Agents Chemother. (1990) 34:368–370.
   PubMed Web of Science ®Google Scholar
• CHIN N-X, NOVELLI A, NEU HC: In vitro activity of lome-floxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other qui-nolones. Antimicrob. Agents Chemother. (1988) 32:656–662.
   PubMed Web of Science ®Google Scholar
• CHIN N-X, GU J-W, YU K-W, ZHANG Y-X, NEU H-C: In vi-tro activity of sparfloxacin. Antimicrob. Agents Chemo-ther. (1991) 35:567–571.
   PubMed Web of Science ®Google Scholar
• CHIN N-X, NEU HC: In vitro activity of WIN 57273 com-pared to the activity of other fluoroquinolones and two beta-lactam antibiotics. J. Antimicrob. Chemother. (1991) 27:781–791.
   PubMed Web of Science ®Google Scholar
• COHEN MA, HUBAND MD, MAILLOUX GB et al.: . In vitro antibacterial activities of PD131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob. Agents Chemother. (1991) 35:141–146.
   Google Scholar
• COHEN MA, HUBAND MD, GAGE et al: In vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J. Antimicrob. Chemother. (1997) 40:205–211.
   PubMed Web of Science ®Google Scholar
• DALHOFF A, PETERSEN U, ENDERMANN R: In vitro activ-ity of Bay 12-8039, a new 8-methoxyquinolone. Chemo-therapy (1996) 42:410–425.
   Google Scholar
• DECRE D, BURE A, PANGON B, PHILIPPON A, BERGOGNE-BEREZIN E: In vitro susceptibility of Rho-dococcus equi to 27 antibiotics. Antimicrob. Agents Che-mother. (1991) 28:311–312.
   Google Scholar
• EDNIE LM, JACOBS MR, APPELBAUM PC: Activities ofgatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob. Agents Che-mother. (1998) 42:2459–2462.
   PubMed Web of Science ®Google Scholar
• ELIOPOULOS GM, KLIMM K, GRAYSON ML: In vitro activ-ity of sparfloxacin (AT-4140, CI-978, PD131501), a new quinolone antimicrobial agent. Diagn. Microbiol. Infect. Dis. (1990) 13:345–348.
   PubMed Web of Science ®Google Scholar
• ESPINOZA AM, CHIN N-X, NOVELLI A, NEU HC: Compara-tive in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob. Agents Chemother. (1988) 32:663–670.
   PubMed Web of Science ®Google Scholar
• FASS RJ: In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob. Agents Chemother. (1997) 41:1818–1824.
   PubMed Web of Science ®Google Scholar
• FENELON LE, MUMTAZ G, RIDGWAY GL: The in vitro an-tibiotic susceptibility of Chlamydia pneumoniae. J. An-timicrob. Chemother. (1990) 26:763–767.
   PubMed Web of Science ®Google Scholar
• FUCHS PC, BARRY AL, PFALLER MA, ALLEN SD, GERLACH EH: Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD131,628, compared with the activity of ciprofloxa-cin against 5,252 clinical bacterial isolates. Antimicrob. Agents Chemother. (1991) 35:764–766.
   PubMed Web of Science ®Google Scholar
• FUNG-TOME J, DESIDERIO JV, TSAI YH, WARR G, KESSLER RE: In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone. Antimi-crob. Agents Chemother. (1989) 33:906–914.
   PubMed Web of Science ®Google Scholar
• GEORGOPOULOS A, MOSER C, BUXBAUM A, STRASCHIL U, GRANINGER W: Antipneumococcal activity of Bay 12–8039 and trovafloxacin in comparison to older qui-nolones. J. Antimicrob. Chemother. (1998) (In Press.)
   Google Scholar
• GOLDSTEIN EJC, CITRON DM: Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxa-cin, enoxacin, and ofloxacin against aerobic and an-aerobic bacteria isolated from bite wounds. Antimicrob. Agents Chemother. (1988) 32:1143–1148.
   PubMed Web of Science ®Google Scholar
• GORZYNSKI EA, AMSTERDAM D, BEAM TR JR, ROTSTEIN C: Comparative in vitro activities of teicoplanin, van-comycin, oxacillin, and other antimicrobial agents against bacteremic isolates of Gram-positive cocci. An-timicrob. Agents Chemother. (1989) 33:2019–2022.
   PubMed Web of Science ®Google Scholar
• HAMMERSCHLAG MR: Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumo-niae. Antimicrob. Agents Chemother. (1994) 38:1873–1878.
   PubMed Web of Science ®Google Scholar
• HOOGKAMP-KORSTANJE JAA: In vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from res-piratory tract infections. J. Antimicrob. Chemother. (1997) 40:427–431.
   PubMed Web of Science ®Google Scholar
• HOPPE J, SIMON CG: In vitro susceptibilities of Borde-tella pertussis and Bordetella parapertussis to seven fluoroquinolones. Antimicrob. Agents Chemother. (1990) 34:2287–2288.
   PubMed Web of Science ®Google Scholar
• KATO N, HARU KATO, KAORI TANAKA-BANDOH, KUNI-MOTO WATANABE, KAZUE UENO: Comparative in vitro and in vivo activity of AM-1155 against anaerobic bac-teria. J. Antimicrob. Chemother. (1997) 40:631–637.
   PubMed Web of Science ®Google Scholar
• KENNY GE, CARTWRIGHT FD: Susceptibility of Myco-plasma pneumoniae to several new quinolones, tetra-cycline, and erythromycin. Antimicrob. Agents Chemother. (1991) 35:587–589.
   PubMed Web of Science ®Google Scholar
• KIMURA M, KISHIMOTO T, NIKI Y, SOEJIMA R: In vitro and in vivo antichlamydial activities of newly devel-oped quinolone antibacterial agents. Antimicrob. Agents Chemother. (1993) 37:801–803.
   PubMed Web of Science ®Google Scholar
• KING A, BETHUNE L, PHILLIPS I: The in vitro activity of temafloxacin compared with other antimicrobial agents. J. Antimicrob. Chemother. (1991) 27:769–779.
   PubMed Web of Science ®Google Scholar
• MARCO F, JONES RN, HOBAN DJ, PIGNATARI AC, YA-MANE N, FREI R: In vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multi-centre international study. J. Antimicrob. Chemother. (1994) 33:647–654.
   PubMed Web of Science ®Google Scholar
• MAPLE PAC, HAMILTON-MILLER JMT, BRUMFITT W: Dif-fering activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (1991) 35:345–350.
   PubMed Web of Science ®Google Scholar
• MAZZULLI T, SIMOR AE, JAEGER R, FULLER S, LOW DE: Comparative in vitro activities of several new fluoro-quinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumo-niae. Antimicrob. Agents Chemother. (1990) 34:467–469.
   PubMed Web of Science ®Google Scholar
• NAKAMURA S, MINAMI A, NAKATA K et al.: In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob. Agents Chemother. (1989) 33:1167–1173.
   PubMed Web of Science ®Google Scholar
• NYE K, SHI YG, ANDREWS JM, ASHBY JP, WISE R: The in vitro activity, pharmacokinetics, and tissue penetra-tion of temafloxacin. J. Antimicrob. Chemother. (1989) 24:415–424.
   PubMed Web of Science ®Google Scholar
• OZAKI M, MATSUDA M, TOMII Y et al: In vitro antibacte-rial activity of a new quinolone, NM 394. Antimicrob. Agents Chemother. (1991) 35:2490–2495.
   PubMed Web of Science ®Google Scholar
• PANKUCH GA, JACOBS MR, APPELBAUM PC: Activity of DU-6589a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. Drugs (1995) 49:235–237.
   PubMedGoogle Scholar
• ROLSTON KVI, LEBLANC B, GOOCH, DH, BODEY GP: In vitro activity of PD117558, a new quinolone against bacterial isolates from cancer patients. J. Antimicrob. Chemother. (1989) 23:363–371.
   PubMed Web of Science ®Google Scholar
• ROLSTON KVI, MESSER M, HO DH: Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer. Antimicrob. Agents Chemother. (1990)34:1812–1813.
   PubMed Web of Science ®Google Scholar
• SADER HS, ERWIN ME, JONES RN: In vitro activity of OPC-17116 compared to other broad-spectrum fluoro-quinolones. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11 :372–381.
   PubMed Web of Science ®Google Scholar
• SADER HS, JONES RN, ALLEN SD et al.: In vitro compari-son activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers. j Chemother. (1993) 5:283–288.
   PubMed Web of Science ®Google Scholar
• SOOKPRANEE T, SOOKPRANEE M, MELLENCAMP MA, PREHEIM LC: Pseudomonas pseudomallei, a common pathogen in Thailand that is resistant to the bacteri-cidal effects of many antibiotics. Antimicrob. Agents Chemother. (1991) 35:484–489.
   PubMed Web of Science ®Google Scholar
• SWANSON RN, HARDY DJ, CHU DTW, SHIPKOWITZ NL,CLEMENT JJ: Activity of temafloxacin against respira-tory pathogens. Antimicrob. Agents Chemother. (1991) 35:423–429.
   PubMed Web of Science ®Google Scholar
• TAYLOR-ROBINSON D, BEBEAR C: Antibiotic suscepti-bilities of mycoplasmas and treatment of mycoplas-mal infections. J. Antimicrob. Chemother. (1997) 40:622–630.
   PubMed Web of Science ®Google Scholar
• VISSER MR, ROZENBERG-ARSKA M, BEUMER, H HOEPEL-MAN IM, VERHOEF J: Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob. Agents Chemother. (1991) 35:858–868.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, BALFOUR JA: Grepafloxacin D. (1997)53 (5) :817–824.
   Google Scholar
• CHAMBERS ST, PEDDIE BA, ROBSON RA, BEGG EJ, BOS WELL DR: Antimicrobial effects of lomefloxacin in vitro. J. Antimicrob. Chemother. (1991) 27:481–489.
   PubMed Web of Science ®Google Scholar
• SPANGLER SK, JACOBS MR, APPELBAUM PC: Activity ofCP-99,219 compared to those of ciprofloxacin, gre-pafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin lazobactam against 489 anaerobes. Antimicrob. Agents Chemother. (1994) 38:2471–2476.
   PubMed Web of Science ®Google Scholar
• BARRY AL, FUCHS PC: In vitro activities of sparfloxacin,tosufloxacin, ciprofloxacin, and fleroxacin. Antimi-crob. Agents Chemother. (1991) 35:955–960.
   PubMed Web of Science ®Google Scholar
• COOPER MA, ANDREWS JM, ASHBY JP, MATTHEWS RS,WISE R: In vitro activity of sparfloxacin, a new qui-nolone antimicrobial agent. J. Antimicrob. Chemother. (1990) 26:667–676.
   PubMed Web of Science ®Google Scholar
• NORRBY SR, JONSSON M: Comparative in vitro activityof PD127,391, a new fluorinated 4-quinolone deriva-tive. Antimicrob. Agents Chemother. (1988) 32:1278–1281.
   PubMed Web of Science ®Google Scholar
• KOTERA Y, MITSUHASHI S: In vitro and in vivo antibac-terial activities of KB-5246, a new tetracycline qui-nolone. Antimicrob. Agents Chemother. (1 98 9) 33:1896–1900.
   Google Scholar
• LEIGH DA, TAIT S, WALSH B: Antibacterial activity oflomefloxacin. J. Antimicrob. Chemother. (1991) 27:589–598.
   PubMed Web of Science ®Google Scholar
• ROBBINS MJ, BASKERVILLE AJ, SANGHRAJKA M et al.:Comparative in vitro activity of lomefloxacin, a difluoro-quinolone. Diagn. Microbiol. Infect. Dis. (1989) 12:65S–765.
   Google Scholar
• ROBLIN PM, HAMMERSCHLAG MR: In vitro activity of anew 8-methoxy-quinolone, Bay 12–8039, against Chla-mydia pneumoniae. Antimicrob. Agents Chemother. 42: 951–952.
   Google Scholar
• UNE T, FUJIMOTO T, SATO K, OSADA Y: In vitro activityof DR-3355, an optically active ofloxacin. Antimicrob. Agents Chemother. (1988) 32:1336–1340.
   PubMed Web of Science ®Google Scholar
• VENEZIA RA, PRYMAS LA, SHAYEGANI A, YOCUM DM: In vitro activities of amifloxacin and two of its metabo-lites. Antimicrob. Agents Chemother. (1989) 33:762–766.
   PubMed Web of Science ®Google Scholar
• WAITES KB, DUFFY LB, SCHMID T: In vitro susceptibili-ties of Mycoplasma pneumoniae, Mycoplasma homi-nis, and Ureaplasma urealyticum to sparfloxacin and PD127391. Antimicrob. Agents Chemother. (1991) 35:1181–1185.
   PubMed Web of Science ®Google Scholar
• BOSWELL FJ, ANDREWS JM, WISE R: Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimi-crob. Agents Chemother. (1997) 41:1377–1379.
   PubMed Web of Science ®Google Scholar
• CULLMANN W, GEDDES AM, WEIDEKAMM E, URWYLER H, BRAUNSTEINER A: Fleroxacin: a review of its chemis-try, microbiology, toxicology, pharmacokinetics, clinical efficacy and safety. Intern. J. Antimicrob. Agents (1993) 2:203–230.
   PubMedGoogle Scholar
• ELIOPOULOS GM, KLIMM K, CT ELIOPOULOS, MJ FER-RARO, RC MOELLERING JR: In vitro activity of CP-99,219, a new fluroqinolone, against clinical isolates of Gram-positive bacteria. Antimicrob. Agents Chemother. (1993) 37:366–370.
   PubMed Web of Science ®Google Scholar
• ASHDOWN LR . In vitro activities of the newer beta-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei. Antimicrob. Agents Chemo-ther. (1988) 32:1435–1436.
   PubMed Web of Science ®Google Scholar
• BARRY AL, JONES RN: In vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J. Antimicrob. Chemother. (1989) 23:527–535.
   PubMed Web of Science ®Google Scholar
• BUSTAMANTE CI, WHARTON RC, WADE JC: In vitro ac-tivity of ciprofloxacin in combination with cef-t az i dim e, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1990) 34:1814–1815.
   PubMed Web of Science ®Google Scholar
• CHOW AW, WONG J, BARTLETT KH: Synergistic interac-tions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrob. Agents Chemother. (1988) 32:782–784.
   PubMed Web of Science ®Google Scholar
• CITRON DM, APPLEMAN MD: Comparative in vitro ac-tivities of trovafloxacin (CP-99,219) against 221 aero-bic and 217 anaerobic bacteria isolated from patients with intraabdominal infections. Antimicrob. Agents Chemother. (1997) 41:2312–2316.
   PubMed Web of Science ®Google Scholar
• GARGALLO-VIOLA D, ESTEVE M, LLOVERA S, ROCA X, GUINEA J: In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob. Agents Chemother. (1991) 35:442–447.
   PubMed Web of Science ®Google Scholar
• PAGANONI R, HERZOG C, BRAUNSTEINER A, HOHL P: Fleroxacin: In vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin. J. Antimicrob. Chemother. (1988) 22 (Suppl. D):3–17.
   Google Scholar
• VISALLI MA, BAJAKSOUZIAN S, JACOBS MR, APPELBAUM PC: Comparative activity of trovafloxacin, alone and in combination with other agents, against Gram-negative nonfermentative rods. Antimicrob. Agents Chemother. (1997) 41:1475–1481.
   PubMed Web of Science ®Google Scholar
• WAKEBE H, IMADA T, YONEDA H: Evaluation of OPC-17116 against important pathogens that cause respira-tory tract infections. (1994) 38:2340–2345.
   Google Scholar
• SMITH RP, BALTCH AL, HAMMER MC, CONROY JV: In vi-tro activities of PD117,596 and reference antibiotics against 448 clinical bacterial strains. Antimicrob. Agents Chemother. (1988) 32:1450–1455.
   PubMed Web of Science ®Google Scholar
• WAKEBE H, MITSUHASHI S: Comparative in vitro activi-ties of a new quinolone, OPC-17116, possessing potent activity against Gram-positive bacteria. Antimicrob. Agents Chemother. (1992) 36:2185–2191.
   PubMed Web of Science ®Google Scholar
• TRAUB WH, SPOHR M: Antimicrobial drug susceptibil-ity of clinical isolates of Acinetobacter species (A. bau- m a nii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrob. Agents Chemother. (1989) 33:1617–1619.
   Google Scholar
• CHAUDHRY AZ, KNAPP CC, SIERRA-MADERO J, WASH-INGTON JA: Antistaphylococcal activities of sparfloxa-cin (CI-978; AT-4140), ofloxacin and ciprofloxacin. Antimicrob. Agents Chemother. (1990) 34:1843–1845.
   PubMed Web of Science ®Google Scholar
• CHIN N-X, FIGUEREDO VM, NOVELLI A, NEU HC: In vitro activity of temafloxacin, a new difluoro quinolone an-timicrobial agent. Eur. J. Clin. Microbiol. Infect. Dis. (1988) 7:58–63.
   PubMed Web of Science ®Google Scholar
• DANGOR Y, MILLER SD, EXPOSTO FL, KOORNHOF HJ: Antimicrobial susceptibilities of southern african iso-lates of haemophilus ducreyi. Antimicrob. Agents Che-mother. (1988) 32:1458–1460.
   PubMed Web of Science ®Google Scholar
• FERNANDES PB, CHU DTW, SWANSON RN et al.: A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimi-crob. Agents Chemother. (1988) 32:27–32.
   PubMed Web of Science ®Google Scholar
• GIRARD AE, GIRARD D, GOOTZ TD, FAIELLA JA, CIMO-CHOWSKI CR: In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against Gram-positive pathogens, Streptococcus pneu-moniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. (1995) 39:2210–2216.
   PubMed Web of Science ®Google Scholar
• GOODING BB, JONES RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Anti-microb. Agents Chemother. (1993) 37:349–353.
   PubMed Web of Science ®Google Scholar
• INAGAKI Y, HORIUCHI S, UNE T, NAKAYA R: In vitro ac-tivity of DR-3355, an optically active isomer of ofloxa-cin, against bacterial pathogens associated with travellers' diarrhea. J. Antimicrob. Chemother. (1989) 24:547–549.
   PubMed Web of Science ®Google Scholar
• KURZYNSKI TA, BOEHM DM, ROTT-PETRI JA, SCHELL RF,ALLISON PE: Antimicrobial susceptibilities of Borde-tella species isolated in a multicenter pertussis surveil-lance project. Antimicrob. Agents Chemother. (1988) 32:137–140.
   PubMed Web of Science ®Google Scholar
• LOUIE A, BALTCH AL, RITZ WJ, SMITH RP Comparative in vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents. J. Antimicrob. Chemo-ther. (1991) 27:793–799.
   Google Scholar
• NEU HC, CHIN N-X: In vitro activity of S-ofloxacin. Anti-microb. Agents Chemother. (1989) 33:1105–1107.
   PubMed Web of Science ®Google Scholar
• ROBLIN PM, HAMMERSCHLAG MR: In vitro activity of a new 8-methoxy-quinolone, Bay 12–8039, against Chla-mydia pneumoniae. Antimicrob. Agents Chemother. 42: 951–952.
   Google Scholar
• ROLSTON, K.V.I., B. LEBLANC, D.H. HO, BODEY GP: In vi-tro activity of PD117596, a new quinolone, against bac-terial isolates from cancer patients. J. Antimicrob. Chemother. (1990) 26:39–44.
   Google Scholar
• BANNERMANN TL, WADIAK DL, KLOOS WE: Susceptibil-ity of Staphylococcus species and subspecies to fleroxacin. Antimicrob. Agents Chemother. (1991) 35:2135–2139.
   PubMed Web of Science ®Google Scholar
• EDELSTEIN PH, EDELSTEIN MAC, WEIDENFELD J, DORR MB: In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneu-mophila pneumonia. Antimicrob. Agents Chemother. (1990) 34:2122–2127.
   PubMed Web of Science ®Google Scholar
• ELIOPOULOS, GM, KLIMM K, RICE LB, FERRARO MJ, MOELLERING JR: Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob. Agents Chemother. (1990) 34:1154–1159.
   PubMed Web of Science ®Google Scholar
• GARCIA-RODRIGUEZ JA, GARCIA SANCHEZ JE, MUNOZ BELLIDO JL, TRUJILLANO I: In vitro activities of irloxa-cin and E-3846, two new quinolones. Antimicrob. Agents Chemother. (1990) 34:1262–1267.
   PubMed Web of Science ®Google Scholar
• SEDLOCK DM, DOBSON RA, DEUEL DM, LESHER GY, RAKE JB: In vitro and in vivo activities of a new qui-nolone, WIN 57273, possessing potent activity against Gram-positive bacteria. Antimicrob. Agents Chemother. (1990) 34:568–575.
   PubMed Web of Science ®Google Scholar
• THOMSON KS, CHARTRAND SA, SANDERS CC, BLOCK SL: Trovafloxacin, a new fluoroquinolone with potent ac-tivity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1997) 41:478–480.
   PubMed Web of Science ®Google Scholar
• GARDIA-RODRIGUEZ JA, GARCIA SANCHEZ JE, MUNOZ BELLIDO JL: In vitro activity of 79 antimicrobial agents against Corynebacterium group D2. Antimicrob. Agents Chemother. (1991) 35:2140–2143.
   PubMed Web of Science ®Google Scholar
• KENNY GE, CARTWRIGHT FD: Susceptibilities of Myco-plasma hominis, Mycoplasma pneumoniae, and Urea-plasma urealyticum to a new quinolone. OPC 17116. Antimicrob. Agents Chemother. (1993) 36:1726–1727.
   Google Scholar
• NEU HC, CHIN N-X: In vitro activity of the new fluoro-quinolone CP-99,219. Antimicrob. Agents Chemother. (1994) 38:2615–2622.
   PubMedGoogle Scholar
• CASSELL GH, WAITES KB, PATE MS, CANUPP KC, DUFFY LB: Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin. Diagn. Microbiol. Infect. Dis. (1989) 12:433–435.
   PubMed Web of Science ®Google Scholar
• CHIRGWIN K, ROBLIN PM, HAMMERSCHLAG MR: (1989) In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob. Agents Che-mother. 33:1634–1635.
   PubMed Web of Science ®Google Scholar
• DOEBBELING BN, PFALLER MA, BALE MJ, WENZEL RP: Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial Gram-negative bloodstream isolates. Eur. J. Clin. Micro-bic)]. Infect. Dis. (1990) 9:298–301.
   PubMed Web of Science ®Google Scholar
• ENDTZ HP, MOUTON JW, JAN G: Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 Gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimi-crob. Agents Chemother. (1997) 41:1146–1149.
   PubMed Web of Science ®Google Scholar
• HARNETT N, BROWNS, KRISHNAN C: Emergence of qui-nolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in On-tario. Canada. Antimicrob. Agents Chemother. (1991) 35:1911–1913.
   PubMed Web of Science ®Google Scholar
• JONES RN, BARRY AL, THORNSBERRY C: Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob. Agents Chemother. (1989) 33:944–950.
   PubMed Web of Science ®Google Scholar
• NEU HC, NOVELLI A, CHIN N-X: Comparative in vitro ac-tivity of a new quinolone, AM-1091. Antimicrob. Agents Chemother. (1989) 33:1036–1041.
   PubMed Web of Science ®Google Scholar
• VAN DER AUWERA P, GRENIER P, GLUPEZYNSKI Y, PIER-ARD D: In vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin. J. Antimicrob. Chemo-ther. (1989) 23:209–219.
   PubMed Web of Science ®Google Scholar
• SIMOR AE, FULLER SA, LOW DE: Comparative in vitro ac-tivities of sparfloxacin (CI-978; AT-4140) and other an-timicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob. Agents Chemother. (1990) 34:2283–2286.
   PubMed Web of Science ®Google Scholar
• BÉBÉAR CM, RENAUDIN H, BOUDJADJA A, BÉBRAR C: In vitro activity of BAY 12–8039, a new fluoroquinolone, against mycoplasma. Antimicrob. Agents Chemother. (1998) 42:703-704. Axel Dalhoff Christian-Albrechts-Universitat Kiel, Institut far Medizinische Mikrobiologie, und Virologie, Brunswiker StraBe 4, 24105 Kiel, Germany
   Google Scholar